Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07821762) titled 'A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barre Syndrome' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: argenx
Condition:
Guillain-Barre Syndrome (GBS)
Intervention:
Biological: Empasiprubart IV
Other: Empasiprubart Placebo IV
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 2026
Target Sample Size: 63
To know more, visit htt...